• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Combined Lectin/Monoclonal Antibody Purging of Bone Marrow for Use in Conjunction with Autologous Bone Marrow Transplantation in the Treatment of Mult

        互联网

        508
        What was thought at the time to be a real breakthrough in myeloma therapy came in 1983 when McElwain reported that complete remission could be gained by means of a single, very high, dose of melphalan (HDM). Between 20 and 30% of patients attain complete remission with HDM (1 ). These observations led directly to exploration of the role of autologous bone marrow rescue following high-dose therapy, since the morbidity and mortality associated with prolonged bone marrow aplasia caused by these doses are unacceptably high (2 ) Most patients with myeloma are relatively old for allogeneic bone marrow transplantation, since graft-vs-host reactions tend to be poorly tolerated in people over 40. Autologous transplantation, however, carries the obvious disadvantage of potential reinfusion of malignant cells. Efforts have therefore been made to develop systems for in vitro purging to remove potentially malignant cells prior to reinfusion of the marrow (3 ,4 ). Although the nature of the initial malignant cell in myeloma is unknown, it is assumed that purging should entail at least the removal of plasma cells and B-lymphocytes
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序